All In Biotech

Drug Trial Radar · NCT05523765

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active Non-Infectious Intermediate-, Posterior-, and Panuveitis

Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Nov 14, 2022

Primary completion

Jul 30, 2024

Study completion Jul 30, 2024

Sponsor

Lead sponsor
Priovant Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).

Conditions

  • Non-infectious Intermediate Uveitis
  • Non-infectious Posterior Uveitis
  • Non-infectious Pan Uveitis

Interventions

  • BrepocitinibDrug

    Oral Brepocitinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Screening up to 28 days after the last dose of study drug at 52 weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    Palo Alto, California

  • Clinical Trial Site

    Pasadena, California

  • Clinical Trial Site

    Lakewood, Colorado

  • Clinical Trial Site

    Waltham, Massachusetts

  • Clinical Trial Site

    St Louis, Missouri

  • Clinical Trial Site

    Palisades Park, New Jersey

  • Clinical Trial Site

    Durham, North Carolina

  • Clinical Trial Site

    Winston-Salem, North Carolina

  • Clinical Trial Site

    Eugene, Oregon

  • Clinical Trial Site

    Nashville, Tennessee

  • Clinical Trial Site

    Bellaire, Texas

  • Clinical Trial Site

    Katy, Texas

  • Clinical Trial Site

    Plano, Texas

  • Clinical Trial Site

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.